184 related articles for article (PubMed ID: 37465593)
1. Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia.
Pillsbury CE; Dougan J; Rabe JL; Fonseca JA; Zhou C; Evans AN; Abukharma H; Ichoku O; Gonzalez-Flamenco G; Park SI; Aljudi A; DeRyckere D; Castellino SM; Rafiq S; Langermann S; Liu LN; Henry CJ; Porter CC
Cancer Res Commun; 2023 Jul; 3(7):1248-1259. PubMed ID: 37465593
[TBL] [Abstract][Full Text] [Related]
2. Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma.
Chen Q; Chen B; Wang C; Hu L; Wu Q; Zhu Y; Zhang Q
Front Immunol; 2023; 14():1159085. PubMed ID: 37234161
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia.
Kumar A; Taghi Khani A; Duault C; Aramburo S; Sanchez Ortiz A; Lee SJ; Chan A; McDonald T; Huang M; Lacayo NJ; Sakamoto KM; Yu J; Hurtz C; Carroll M; Tasian SK; Ghoda L; Marcucci G; Gu Z; Rosen ST; Armenian S; Izraeli S; Chen CW; Caligiuri MA; Forman SJ; Maecker HT; Swaminathan S
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37217248
[TBL] [Abstract][Full Text] [Related]
4. IL12 Abrogates Calcineurin-Dependent Immune Evasion during Leukemia Progression.
Rabe JL; Gardner L; Hunter R; Fonseca JA; Dougan J; Gearheart CM; Leibowitz MS; Lee-Miller C; Baturin D; Fosmire SP; Zelasko SE; Jones CL; Slansky JE; Rupji M; Dwivedi B; Henry CJ; Porter CC
Cancer Res; 2019 Jul; 79(14):3702-3713. PubMed ID: 31142509
[TBL] [Abstract][Full Text] [Related]
5. Alteration of the immune environment in bone marrow from children with recurrent B cell precursor acute lymphoblastic leukemia.
Mikami T; Kato I; Wing JB; Ueno H; Tasaka K; Tanaka K; Kubota H; Saida S; Umeda K; Hiramatsu H; Isobe T; Hiwatari M; Okada A; Chiba K; Shiraishi Y; Tanaka H; Miyano S; Arakawa Y; Oshima K; Koh K; Adachi S; Iwaisako K; Ogawa S; Sakaguchi S; Takita J
Cancer Sci; 2022 Jan; 113(1):41-52. PubMed ID: 34716967
[TBL] [Abstract][Full Text] [Related]
6. Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.
Haas Q; Markov N; Muerner L; Rubino V; Benjak A; Haubitz M; Baerlocher GM; Ng CKY; Münz C; Riether C; Ochsenbein AF; Simon HU; von Gunten S
Front Immunol; 2022; 13():996746. PubMed ID: 36211376
[TBL] [Abstract][Full Text] [Related]
7. IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies.
Cai B; Liu Y; Chong Y; Zhang H; Matsunaga A; Fang X; Pacholczyk R; Zhou G; Cowell JK; Hu T
Mol Cancer; 2021 Dec; 20(1):165. PubMed ID: 34906138
[TBL] [Abstract][Full Text] [Related]
8. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
[TBL] [Abstract][Full Text] [Related]
9. Obesity accelerates immune evasion of non-small cell lung carcinoma via TFEB-dependent upregulation of Siglec-15 and glycolytic reprogramming.
Zhang C; Zhou L; Li S; Zhao J; Meng X; Ma L; Wang Y; Li C; Zheng L; Ming L
Cancer Lett; 2022 Dec; 550():215918. PubMed ID: 36150633
[TBL] [Abstract][Full Text] [Related]
10. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow infiltrated Lnc-INSR induced suppressive immune microenvironment in pediatric acute lymphoblastic leukemia.
Wang Y; Yang X; Sun X; Rong L; Kang M; Wu P; Ji X; Lin R; Huang J; Xue Y; Fang Y
Cell Death Dis; 2018 Oct; 9(10):1043. PubMed ID: 30310051
[TBL] [Abstract][Full Text] [Related]
12. Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics.
Poveda-Garavito N; Combita AL
Front Immunol; 2023; 14():1325255. PubMed ID: 38299154
[TBL] [Abstract][Full Text] [Related]
13. Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies.
Alvarez Calderon F; Kang BH; Kyrysyuk O; Zheng S; Wang H; Mathewson ND; Luoma AM; Ning X; Pyrdol J; Cao X; Suvà ML; Yuan GC; Wittrup KD; Wucherpfennig KW
Blood; 2024 Mar; 143(12):1124-1138. PubMed ID: 38153903
[TBL] [Abstract][Full Text] [Related]
14. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer.
Li TJ; Jin KZ; Li H; Ye LY; Li PC; Jiang B; Lin X; Liao ZY; Zhang HR; Shi SM; Lin MX; Fei QL; Xiao ZW; Xu HX; Liu L; Yu XJ; Wu WD
Cancer Lett; 2022 Apr; 530():142-155. PubMed ID: 35077803
[TBL] [Abstract][Full Text] [Related]
15. Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line.
Wang L; Zhang Y; Anderson E; Lamble A; Orentas RJ
Front Immunol; 2022; 13():825364. PubMed ID: 35222407
[TBL] [Abstract][Full Text] [Related]
16. Expansion and activation of granulocytic, myeloid-derived suppressor cells in childhood precursor B cell acute lymphoblastic leukemia.
Liu YF; Chen YY; He YY; Wang JY; Yang JP; Zhong SL; Jiang N; Zhou P; Jiang H; Zhou J
J Leukoc Biol; 2017 Aug; 102(2):449-458. PubMed ID: 28619949
[TBL] [Abstract][Full Text] [Related]
17. C-kit receptors in childhood malignant lymphoblastic cells.
Sykora KW; Tomeczkowski J; Reiter A
Leuk Lymphoma; 1997 Apr; 25(3-4):201-16. PubMed ID: 9168431
[TBL] [Abstract][Full Text] [Related]
18. Siglec-9 Regulates an Effector Memory CD8
Haas Q; Boligan KF; Jandus C; Schneider C; Simillion C; Stanczak MA; Haubitz M; Seyed Jafari SM; Zippelius A; Baerlocher GM; Läubli H; Hunger RE; Romero P; Simon HU; von Gunten S
Cancer Immunol Res; 2019 May; 7(5):707-718. PubMed ID: 30988027
[TBL] [Abstract][Full Text] [Related]
19. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
[TBL] [Abstract][Full Text] [Related]
20. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
